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Identification and Characterization of Mitochondrial Genome Concatemers in
AIDS-Associated Lymphomas and Lymphoma Cell Lines
Felipe Bedoya
ABSTRACT

Despite recent advances in the understanding of the molecular bases of
hematological malignancies, the specific mechanisms on how they originate
and why some subtypes are more prevalent than others still remain to be
elucidated.

These two important aspects have been even more difficult to

analyze when dealing with individuals under immune suppression because
other factors must be considered. Questions still remain as to why individuals
with AIDS tend to develop lymphoproliferative disorders differently from those
observed in individuals under iatrogenic immunosuppressive therapy. Most of
lymphomas occurring in transplant recipients are B-cell neoplasias typically
associated with Epstein-Barr virus (EBV) infection. In contrast, only about 50%
of lymphomas of patients with AIDS are associated with lymphotrophic
herpesviruses such as EBV and Kaposi’s sarcoma-associated herpesvirus
(KSHV). No known infectious agent has been detected in the remaining 50% of

x

AIDS-associated lymphomas, suggesting the involvement of novel viruses or
unique molecular mechanisms.

Since most oncogenic viruses persist as

episomal circular viral genomes in the nuclei of tumor cells, we developed a
method to visualize and identify covalently closed circular DNA (cccDNA) in
lymphoma samples.

Although this study revealed no novel viruses, we

identified concatemers of the mitochondrial genome in all lymphoma samples
tested.

We further studied in detail one AIDS-associated lymphoma

(denominated EL) whose mitochondrial DNA primarily consisted of tandem
head-to-tail genome duplications. Insertion of cytosine residues was noted in
the EL mitochondrial genome sequence near the origin of replication. EL cells
responded weakly to Fas-apoptotic stimulus, displayed reduced mitochondrial
activity and mass, and produced higher levels of reactive oxygen species
(ROS) than control cells.

Screening of several other AIDS-associated

lymphomas and established lymphoma cell lines revealed a different kind of
mitochondrial genome concatemers consisting of interlinks of DNA monomer
molecules.

Concatemers were not detected in normal T-lymphocytes

suggesting an association with neoplastic transformation.

This dissertation

describes the two distinct types of mitochondrial genome concatemers
identified in transformed lymphoid cells and presents a detailed analysis of their
structure and implications in cellular homeostasis.

xi

Introduction

AIDS-associated lymphomas

After the acknowledgment of HIV as the causative agent of AIDS, it was
soon recognized that the incidence of lymphoma in HIV-infected patients
greatly exceeded that in the general population. The relative risk of nonHodgkin’s lymphoma (NHL) is increased 60-200 fold in individuals with AIDS
(12, 58, 147). The increased risk of lymphoma has been attributed to multiple
factors, including the capability of the retrovirus itself to induce transformation
(86, 101), the cytokine dysregulation and immunosuppression associated with
the disease (28, 82), and the opportunistic infections caused by lymphotrophic
γ-herpesviruses such as Epstein–Barr virus (EBV) and Kaposi’s sarcomaassociated herpesvirus (KSHV) (16, 89, 136, 209). Several AIDS-associated
lymphoma subtypes have been classified according to the heterogeneous
morphology observed in patients. The WHO categorizes the HIV-associated
lymphomas into (1) those also occurring in immunocompetent patients, (2)
those occurring more specifically in HIV-positive patients, and (3) those also
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occurring in patients with other forms of immunosuppression (Table 1).
Notably, the majority of these lymphomas are aggressive B-cell neoplasms that
also occur in immunocompetent patients (17, 148).

Highly active antiretroviral therapy (HAART) has been reported to both
increase and decrease the incidence of different lymphoma subtypes. For
example, immunoblastic diffuse large B-cell lymphoma (DLBCL) was reduced
from 38% in the pre-HAART era to 19% in the post-HAART era. Also, primary
CNS lymphoma incidence decreased from 28% to 17%. However, this trend
has not been observed in all AIDS-related lymphomas, centroblastic DLBCL
increased from 21% to 44% of cases, and Burkitt’s lymphoma increased from
4% to 9% (43, 135). Several studies have shown that the level of
immunosuppression is also associated to the lymphoma subtype that develops
in AIDS-patients. For instance, Burkitt’s and centroblastic DLBCL are
commonly diagnosed in partially immunodeficient individuals, whereas primary
effusion lymphoma (PEL) and immunoblastic DLBCL are most often present in
AIDS-patients suffering from severe immunodeficiency (16, 63).
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•

Burkitt's and Burkitt's-like lymphoma

•

Diffuse large B-cell lymphoma (DLBCL)
• Centroblastic

1) Lymphoma also
occurring in
immunocompromised
patients

2) Lymphoma
occurring more
specifically in HIVpositive patients

3) Lymphoma also
occurring in other
immunodeficiency
states

• Immunoblastic (including primary CNS
lymphoma)
•

Extranodal marginal zone lymphoma of MALT
type

•

Peripheral T-cell lymphoma

•

Classical Hodgkin's lymphoma (HL)

•

Primary effusion lymphoma (PEL)

•

Plasmablastic lymphoma of the oral cavity type

•

Polymorphic B-cell lymphoma (PTLD-like)

Table 1. Classification of AIDS-associated lymphomas according to WHO.
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Mitochondria

Mitochondria are semi-autonomous subcellular organelles essential for
normal cell physiology and cellular homeostasis (196). Mitochondria are the
only organelles that contain their own genome and protein synthesis machinery
̶ possibly due to their prokaryotic endosymbiont ancestry (98, 196). They are
motile and undergo frequent changes in morphology and number through
fusion and fission events. Even in the same cell, mitochondria can adopt a
different range of morphologies (23, 42). It is in the mitochondria where many
important metabolic reactions take place such as the urea cycle, lipid
metabolism, steroid hormone and porphyrin synthesis and interconversion of
amino acids (164, 195). Moreover, mitochondria play a central role in complex
physiological processes including cellular proliferation, differentiation, apoptosis
(60, 139, 150), and in cellular processes like glucose sensing, insulin regulation
(15), cellular Ca2+ and ROS homeostasis (123, 176). Hence, it is not surprising
that mitochondrial dysfunction has been associated with degenerative
diseases, aging and cancer (30, 61, 155, 198).
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Figure 1. The mitochondrion.
Diagram showing energy (ATP) production from oxidative phosphorylation (OXPHOS), reactive
oxygen species (ROS) production, and initiation of apoptosis through the mitochondrial
permeability transition pore (mtPTP). The OXPHOS complexes, designated I to V, are complex
I (NADH: ubiquinone oxidoreductase), complex II (succinate: ubiquinone oxidoreductase),
complex III (ubiquinol: cytochrome c oxidoreductase), complex IV (cytochrome c oxidase), and
+
complex V (H -translocating ATP synthase). Pyruvate from glucose enters the mitochondria via
pyruvate dehydrogenase (PDH), generating acetyl-CoA, which enters the TCA cycle by
combining with oxaloacetate. Lactate dehydrogenase (LDH) converts excess pyruvate to
lactate. The voltage-dependent anion channel (VDAC) allows passage of small molecules
through the inner and outer membrane. VDAC together with ANT and Bax are thought to come
together at the mitochondrial inner and outer membrane contact points to create the
mitochondrial permeability transition pore (mtPTP). The mtPTP interacts with the pro-apoptotic
Bax, anti-apoptotic Bcl2 and the benzodiazepine receptor (BD). The opening of the mtPTP is
associated with the release of cytochrome c (Cytc) and several pro-apoptotic factors that
interact with and activate cytosolic Apaf-1, which then binds to and activates procaspase-9. The
activated caspase-9 then initiates the proteolytic degradation of cellular proteins ending in
apoptosis.
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The mitochondrial genome

The mammalian mitochondrial genome is a covalently closed circular
(ccc) duplex DNA (mtDNA) with species-specific contour length of about 5μm
and nucleotide composition range around 16 Kbp (41, 98). In humans, the
mtDNA encodes 13 genes involved in the respiratory chain: 7 genes for
complex I (NADH-dehydrogenase-ubiquinone reductase): NADH
dehydrogenase subunit 1 (ND1), ND2, ND3, ND4, ND4L, ND5 and ND6; 1
gene for complex III (ubiquinol-cytochrome c reductase): cytochrome b; 3
genes for complex IV (cytochrome c oxidase): Cytochrome c oxidase subunit 1
(COX1), COX2 and COX3, and 2 genes for complex V (ATP synthetase):
ATPase6 and Atpase8 (1).

The mtDNA also encodes 22 transfer RNAs, and two ribosomal RNAs
known as 12S and 16S rRNAs, that are exclusive for the translation of the 13
mtDNA protein-coding genes. All of the peptides and mature transcripts
derived from the mtDNA are necessary for the proper function of the oxidative
phosphorylation (OXPHOS) machinery, which is the main biochemical pathway
for the synthesis of ATP(1, 197).

In average, 200-10,000 copies of mtDNA are present in a single cell
depending on cell type and cellular energy demand. At birth, most (if not all) of
6

the mtDNA copies are identical (homoplasmic) owing to their maternal origin
(65, 108). However, degenerative cellular processes (i.e. ageing, disease, etc.)
have been implicated in the causality of several mitochondrial and mtDNA
abnormalities, and vice versa (42, 184, 198). Unlike nuclear DNA, the mtDNA
is constantly turned over and replicated during the whole cell cycle in normal
cells (77, 80).

To date, a large number and ample variety of mtDNA mutations have
been described, and over 200 human disorders are associated with specific
point and frame-shift mutations, fusions, partial deletions, or depletion of
mtDNA. For instance, several mtDNA mutations have been reported recently in
human colorectal cancers, and bladder, head, neck and lung tumors (14, 27,
30, 73, 95, 184).

Clinically defined syndromes such as MELAS (mitochondrial myopathy,
encephalopathy, lactic acidosis and stroke-like episodes), MERRF (myoclonus
epilepsy and ragged-red fibres), and Kearns-Sayre syndrome (retinitis
pigmentosa, progressive external ophthalmoplegia, ataxia and heart conduction
defects) have all been directly associated to atypical mtDNA forms (94, 172,
214).
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Figure 2. The human mitochondrial genome.
Human mtDNA-encoded genes: NADH dehydrogenase subunits of complex I
(ND1-ND6 and ND4L), cytochrome b (Cytb) of complex III, cytochrome c
oxidase subunits of complex IV (COX1-3), ATP synthase subunits 6 and 8 of
complex V, rRNAs (12S and 16S), and tRNAs (indicated by the one-letter
amino acid symbol). Also showing control region (D-loop) and arrows
indicating the promoters for transcription of the heavy (HSP) and light (LSP)
strand of mtDNA and the origins of leading (OH) and lagging (OL) strand
replication. Modified from reference 31.
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Particularities of the mitochondrial DNA

In comparison to the nuclear genome, several characteristics have been
exclusively attributed to the mtDNA:

1) Polyploidy: Most mammalian cells contain hundreds of mitochondria
and each mitochondrion contains several copies (2-10) of the mtDNA (131). It
is believed that a single individual has identical copies of the mtDNA; however,
mutations can arise and co-exist with wild-type mtDNA, a phenomenon known
as heteroplasmy. Different levels of heteroplasmy have been reported in
different cell types and tissues due to random segregation of mitochondria (and
mtDNA) at cell division (174). In order to produce a particular phenotype (e.g.
disease), the level of heteroplasmy has to reach a certain percentage known as
the “threshold effect”, usually around 60-80% of total mtDNA (44, 152).

2) Non-mendelian (maternal) inheritance: A mammalian oocyte
contains around 100,000 copies of the mitochondrial genome ̶ a large amount
of mtDNA in comparison with the mere 100 copies carried in a single sperm cell
(most of them surrounding the sperm tail to provide ATP for motility) (175).
Therefore, during fertilization, the sperm head (containing the nucleus) is fused
9

to the egg, and basically no mitochondria are transferred in the process; the
few mitochondria that could enter in the newly formed zygote are actively
eliminated by a ubiquitin-dependent mechanism (180, 208). Recently, new
evidence showing that paternal mtDNA can be present in the offspring has
been reported, although the mechanism remains unknown (93, 167).

3) Evolution rate: There are no histones in the mitochondrion;
therefore, the mtDNA is less protected than the nuclear genome (168).
Moreover, the mtDNA is physically associated with the inner mitochondrial
membrane where damaging ROS are present, and less-efficient DNA repair
mechanisms have been identified in mitochondria (168, 177, 206). Together,
these reasons explain why the mtDNA has higher mutation rates than the
nuclear DNA, and provide a hint on how somatic accumulation of mtDNA
mutations can play a role in human aging and disease. On the other hand,
single nucleotide polymorphisms (SNPs) in the mtDNA have been mapped and
have served as a tool for human population genetics and evolutionary studies
(62, 201).

4) Divergent genetic code: Mitochondrial genes are translated by a
mtDNA-restricted translation machinery that utilizes a genetic code distinct from
10

the universal genetic code. For example, in mammals, UGA rather than a
termination codon codes for tryptophan, and AGA and AGG are termination
codons instead of encoding arginine (7).

5) Gene organization: One of the main characteristics of mammalian
mtDNA is its compact gene organization. All the genes are next to each other
or separated by a few nucleotides with no introns and no 5’ or 3’ non-coding
regions (1). In human mtDNA, overlapping occurs between genes ATPase 6
and ATPase 8 (46 nt in common), and between ND4 and ND4L (7 nt in
common) (6) (Figure 2). And for several genes, the termination codon is added
by poly-adenylation of the mRNA, since it is not encoded in the mtDNA (32).
The tRNAs are interspersed between genes and play an important role in RNA
processing (140). Post-transcriptional excision of tRNAs from polycistronic
messages is mediated by the mitochondrial RNase P enzyme (encoded in the
nucleus). This process of excision is necessary for the expression of the
mitochondrial genomic information (45, 189).

The overall genetic content and organization of vertebrate mitochondrial
genomes is highly conserved; however, the mtDNA sequence and the position
of regulatory elements for replication and transcription vary considerably even
within a single species (168). Two major non-coding regions are present in the
11

mammalian mtDNA: the D-loop and the origin of replication for the light (L)
strand (OL). The D-loop (~1kb) contains the origin of replication for the heavy
or H-strand (according to its higher guanine content) and the promoters for both
H- and L-strand transcription (168, 183). Also, within the D-loop highly
conserved regions are found throughout several metazoan mtDNAs. They are
known as the conserved sequence boxes (CSB I-III) and the terminationassociated sequences (TASs) (47, 168). The OL is a 30 nucleotide-long
segment at about two-thirds of the mtDNA (from OH) that is located inside a
tRNA cluster known as the “WANCY” region (from the amino acids single-letter
nomenclature) (Figure 3) (34, 47).
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Figure 3. Schematic representation of the mammalian D-loop.
Diagram showing the non-coding regulatory D-loop and transcription
termination regions. Also, the main factors and cis-elements involved in
mtDNA transcription and replication. DNA polymerase-γ (DNApol-γ), exclusive
for mtDNA replication. The mitochondrial RNA polymerase (POLRMT) binds to
mitochondrial transcription factors (MTFs) bound to regions upstream of
promoters for light-strand (LSP) and heavy-strand (HSP1 and HSP2)
transcription. RNase P is a ribonucleoprotein that processes the transcripts
from LSP to generate the primers for heavy-strand replication from its origin
(OH). Conserved sequence boxes (CSB I-III) and termination-associated
sequences (TAS) important for transcription and replication of the heavy-strand.
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Mitochondrial DNA transcription

In human mtDNA, independent promoter regions for transcription
initiation of each strand have been described (33). The light-strand (lower
guanine content) encompasses one promoter region known as LSP, and the
heavy-strand contains two, HSP1 and HSP2 (32, 33). Polycistronic precursor
RNAs (some of them nearly full-genome long) are transcribed from both LSP
and HSPs by the mitochondrial DNA-dependent RNA polymerase (POLRMT)
(13). Mature mRNAs and rRNAs are then separated by excision of the tRNAs
(flanking all the protein-coding genes). Processing of the mitochondrial RNA
precursors is carried out by RNase P. This mechanism of RNA processing has
been described as a “tRNA punctuation model” (13, 140, 189).

Since POLRMT cannot directly bind DNA and initiate transcription on its
own, it requires assistance from mitochondrial transcription factors (mtTFA and
mtTFB) that associate with specific regions upstream of the mtDNA promoters
(5, 46). Although ubiquitous expression, there is substantial evidence
indicating that the mammalian mitochondrial transcription machinery is
differentially regulated throughout tissues (48, 161). Notably, all the proteins
involved in mtDNA transcription and production of mature mtRNAs are encoded
in the nuclear genome (156).

14

Since mitochondrial gene expression is essential for OXPHOS, an
appealing idea, that has not been fully addressed so far, is how mtDNA
transcription is coordinated with cellular energy demand. Different cell and
tissue types have energetic demands that vary according to their physiological
state, which in turn require different rates of mitochondrial biogenesis (165,
194). The mechanisms that govern mitochondrial biogenesis are poorly
understood; however, some factors and pathways have been characterized for
specific situations. During cellular proliferation, for example, upregulation of
mitochondrial and nuclear genes necessary for the proper assembly and
function of the OXPHOS system have been documented (13, 163). This
process requires the participation of protein activators such as nuclear
respiratory factors 1 and 2 (NRF-1 and NRF-2), CREB, Sp-1 and others (160,
162). Equally necessary, are coactivators that interact with nuclear DNAbinding proteins such as PGC-1α and PRC, in order to regulate gene
transcription in response to environmental and proliferative signals (2, 83, 160).

MtDNA-transcription has been shown to be also regulated by
intracellular ATP levels (66, 128, 192). Shuey et al. demonstrated that a
“sensing mechanism” of the amounts of ATP is responsible for the differential
expression of mitochondrial transcripts, since ATP is required 15- to 20-fold
more over the other NTPs for transcription (170). Furthermore, recent evidence
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shows that differential transcription from LSP versus HSP1 occurs depending
on ATP availability, resulting in altered mRNA and rRNA profiles (51, 134).

Mitochondrial DNA replication

Mitochondria possess a unique protein system devoted exclusively to
mtDNA replication. Most of the components of this repertoire have been
characterized; however, some elements still remain to be identified since there
seems to be no apparent mitochondrial counterpart for the corresponding
nuclear enzymatic activity (e.g. primase for mtDNA light-chain synthesis) (46).
An important finding in the study of mtDNA is that replication is totally
dependent on transcription. This is due to the fact that replication of the heavy
strand at the origin (OH) is primed by a short RNA transcribed from the LSP
region (24, 25). This phenomenon has been demonstrated by several groups.
Chang D. et al. showed that using mitochondrial transcription assays in vitro
some of the nascent transcripts remain bound to the mtDNA at the OH (26). And
Kang et al. detected in vivo RNA-primed DNA strands using the polymerase
chain reaction analysis (81).
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Although the exact mechanism is still under intense debate, two major
models of mtDNA replication have been proposed (31). The first one (in terms
of years from publication) is the strand-displacement replication, and the other
is the strand-coupled replication. The strand-displacement mechanism was
initially proposed in 1982 by Clayton et al. from direct observation of purified
mtDNA by electron microscopy (34). This mode of mtDNA replication
resembles to that of bacterial plasmids (e.g. ColE1), but is different from that of
chromosomal DNA replication of both eukaryotes and eubacteria. It posits that
replication of the heavy- (leading) strand initiates at OH and proceeds
unidirectionally until it reaches two-thirds of the genome, where the origin of the
light- (lagging) strand (OL) is exposed on the displaced parental strand,
initiating replication in the opposite direction (Figure 4). This model, also called
the asynchronous, strand-asymmetric replication model, introduces the concept
of a displacement loop (D-loop) observed at high frequency in the purified
mtDNA analyzed. The D-loop was described as a third short heavy DNA strand
associated to the parental mtDNA of about 1Kb of length and presumably
formed by 5’ to 3’ mtDNA synthesis arrest at the termination-associated
sequences (TASs) (168). D-loops of different size have also been detected in
mtDNA from other species (100, 159).
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Figure 4. Strand-displacement model of mammalian mtDNA replication.
Closed circular mtDNA enters replication by formation of D-loop. Migration of
the heavy-strand continues unidirectionally displacing the parental strand until it
reaches two-thirds of the mtDNA, where the origin for light-strand (OL) is
exposed initiating replication in the opposite direction.
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The strand-coupled mechanism of replication was proposed more
recently by Jacobs and colleagues (70). It is based on the detection of
replicative mtDNA intermediates in 2D-gels. This technique separates DNA
fragments based on size and shape. Therefore, replication intermediates are
expected to resolve in predictable ways. In case both DNA strands replicate
simultaneously they tend to form a replication fork, which can be detected as a
“Y arc” in 2D-gels. Such Y arcs were unambiguously identified when analyzing
mtDNA from human placenta and mouse liver, underscoring the existence of a
strand-synchronous replication mechanism; however, single-stranded
intermediates were also detected meaning that a combination, rather than a
mutually exclusive mode, of both mechanisms might be present in mammalian
mitochondria (149) (Figure 5).

An interesting observation perhaps is that not all genes required for
mammalian mtDNA replication have evolved from a prokaryotic ancestor. For
example, POLRMT, the catalytic subunit of mtDNA polymerase (POLγA), and
the mtDNA helicase (TWINKLE) are similar to proteins encoded by
bacteriophages of the T-odd lineage, which include bacteriophages T3 and T7.
Therefore, it has been proposed that some genes necessary for replication and
expression of the mtDNA were acquired from a T-odd phage ancestor early in
the evolution of eukaryotic organisms, possibly during the time when
mitochondrial endosymbiosis occurred (21, 171).
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Figure 5. Strand-coupled model of mammalian mtDNA replication.
Closed circular mtDNA enters replication by formation of a D-loop that
facilitates bidirectional polymerization of leading and lagging strands from origin
OH (it could also start from OL) at the same time (synchronous). Migration
could proceed around the genome with lagging-strand replication being the
result of multiple short-fragment (‘Okazaki’) synthesis.
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Oxidative phosphorylation

Mitochondria generate energy by oxidizing metabolites derived from our
dietary carbohydrates (TCA cycle) and fats (β-oxidation) to generate heat and
ATP (Figure 1) (198). Embedded in the inner mitochondrial membrane, there is
a system of electron carrier complexes, also known as the electron transport
chain (ETC). The main function of the ETC is to transfer electrons by a multistep redox process from TCA cycle products (NADH and FADH2) to oxygen,
which is reduced to water (36, 49, 198). Electrons are initially donated from
NADH and FADH2 to complex I (NADH dehydrogenase) or to complex II
(succinate dehydrogenase), respectively. Ubiquinone (also coenzyme Q or
CoQ) carries these electrons to give ubisemiquinone (CoQH•) and then
ubiquinol (CoQH2). Ubiquinol transfers its electrons to complex III
(ubiquinol:cytochrome c oxidoreductase), which transfers them to cytochrome
c, an electron carrier protein located within the intermembrane space. Then,
cytochrome c carries the electrons to complex IV (cytochrome c oxidase or
COX) and finally to ½O2 to give H2O. In order to transfer electrons, each ETC
complex contains multiple electron carriers. Complexes I, II, and III encompass
several iron-sulfur (Fe-S) centers, whereas complexes III and IV contain the b +
c1 and a + a3 cytochromes, respectively (169, 199, 200, 202).
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The energy released by the flow of electrons through the ETC is used to
pump protons out of the mitochondrial inner membrane through complexes I,
III, and IV. The efflux of protons creates a pH gradient and an electrochemical
gradient across the mitochondrial inner membrane. This proton gradient is
harnessed by complex V (F0F1 ATP synthase) for ATP production. As protons
flow back into the mitochondrial matrix through a proton channel in complex V,
ADP and inorganic phosphate (Pi) are bound, condensed, and released in the
matrix as ATP. Then, matrix ATP is exchanged for cytosolic ADP through the
adenine nucleotide translocator (ANT) (Figure 1). As protons flow through the
ATP synthase proton channel, the proton gradient is depolarized. Since the
ETC is coupled to ATP synthesis, this process is known as oxidative
phosphorylation (OXPHOS). The coupling efficiency of the OXPHOS system
determines the efficiency of producing ATP from dietary calories (36, 172, 198,
202).

Mitochondria and cancer

Cancer cells utilize glycolytic pathways for energy generation while
upregulating their aerobic respiratory activity. This metabolic change
discovered by Otto Warburg over 60 years ago, was one of the first phenotypic
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alterations recognized in cancerous cells that confers a survival advantage (59,
204, 215). Warburg took advantage of new techniques for simultaneously
measuring gas consumption and lactate production in tumor slices either in the
presence or absence of oxygen. Surprisingly, in the presence of oxygen, the
rapidly growing tumor cells consumed glucose at a higher rate and secreted
elevated amounts of lactate compared to normal cells (204). More recently,
Positron Emission Tomography (PET) imaging technique of fast-growing and
metastatic human cancers using the glucose analogue tracer 18fluorodeoxyglucose (FDG) has confirmed Warburg’s observations (57, 119,
129).

The first compelling evidence that mitochondrial dysfunction was
associated with tumorigenesis was presented less than a decade ago when
mutations in succinate dehydrogenase (SDH) or fumarate hydratase (FH), both
enzymes of the TCA cycle, were found to be initiating events of familial
paraganglioma or leiomyoma and of papillary renal cell cancer, respectively
(10, 188). To demonstrate that mtDNA mutations can also contribute to the
oncogenicity of tumors, a known pathogenic mtDNA mutation was introduced
into the prostate cancer cell line PC3, which resulted in increased
tumorigenicity (143). Furthermore, neoplastic transformation has been found to
produce marked changes in the expression of both nuclear and mitochondrial
OXPHOS genes (133, 190). These changes have been also proposed to occur
23

in tumors developed in a tissue-specific fashion (14, 27, 198). A study
performed in Caenorhabditis elegans showed that inactivation of the Cytb (a
mtDNA-encoded gene) subunit of complex II markedly increases mitochondrial
ROS production (72). Thus, ROS production appears to be the factor that links
mitochondrial defects to neoplastic transformation and metastasis (74, 210).
However, the precise mechanism by which mitochondrial RNA and/or ROS
levels increase in cancerous cells still remains unclear (35).

On the other hand, the direct role that mitochondria play in apoptosis has
been extensively studied during the past two decades. For instance, loss of
mitochondrial membrane potential is thought to contribute to cell death by
disruption of normal mitochondrial function (20, 76, 96). Further, mitochondrial
outer membrane permeabilization (MOMP) leads to the release of proapoptotic
factors such as cytochrome c and AIF. Therefore, several MOMP inhibitors
(e.g. Bcl-2, Bcl-XL, VDAC isomers, hexokinase II) have been described and are
currently targeted in the chemotherapeutic treatment of cancer (3, 53, 203).
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Objectives

In comparison to the immunocompetent population, AIDS and posttransplant patients have a significant increase of developing virus-induced
cancers. Lymphoproliferative disorders (LD) in particular, have been found to
be diagnosed more frequently than other types of neoplasias. Nevertheless, it
is still unknown why some LD subtypes are more prevalent than others in AIDS
versus post-transplant patients. The discovery of new viruses associated with
cancer during the last two decades and the immunosuppressive state of these
individuals suggest that unidentified infectious agents might be responsible for
inducing neoplastic transformation within this context.

Since γ-herpesviruses (e.g. KSHV and EBV) have been directly linked to
specific cases of LD in humans (16, 136, 166), one of our main goals was to
determine whether EBV- and KSHV-negative AIDS-associated lymphomas
could be caused by a large DNA virus. Since γ-herpesviruses are maintained
as circularized extrachromosomal nuclear genome copies during latency (37), it
was investigated whether these LD samples could contain novel episomal
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DNA. Despite the fact that no novel DNA was detected in the samples tested,
dimers and concatemers of the mitochondrial genome were identified.
Furthermore, independent of HIV infection, established lymphoma cell lines
also harbored this type of mtDNA. In this dissertation, a detailed analysis of the
mtDNA concatemers identified in a case of AIDS-associated lymphoma (EL) is
presented. This work also shows evidence that formation of mtDNA
concatemers and dimers are associated with neoplastic transformation by
immortalizing normal human T-cells with Herpesvirus saimiri. Further studies
on this area might reveal a new avenue for the therapeutic treatment of
lymphoma.

The following aims were designed for this dissertation project:

1. To characterize the cccDNA identified in a case of EBV- and KSHV-negative
AIDS-associated lymphoma (EL).

2. To determine if mitochondrial genome concatemers can influence
mitochondrial and cellular function.

3. To determine if mitochondrial genome concatemers are associated with
immortalization of normal human T-cells with Herpesvirus saimiri.
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Materials and methods

Primary AIDS-associated lymphomas and human T-cell samples
Twelve non-Hodgkin’s lymphoma samples from HIV-positive patients
were obtained through the Division of Cancer Treatment and Diagnosis at the
National Cancer Institute. Samples were cultured in RPMI 1640 medium
supplemented with 4 mM L-glutamine, 10% fetal bovine serum and 50μg/ml
gentamycin. Peripheral blood mononuclear cells were isolated from blood bank
donor samples and T-cell cultures were obtained by PHA stimulation (10 μg/ml)
of mononuclear cells for 3 days, then cultured in medium containing 50U/ml of
IL-2.

Method for detection of cccDNA
Live lymphoid or AIDS-associated lymphoma cells were selected by
Lymphoprep™ (ProGen), according to manufacturer’s protocol. 1x106 cells
were loaded in each well of a vertical 0.8% agarose gel in 10% Ficoll buffer
(54). Cell lysis buffer containing 5% Ficoll, 1% SDS, 1mg/ml pronase and
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0.05% xylene cyanol green was layered on top of the cell samples.
Electrophoresis was carried at 0.8 V/cm for 3 h, then increased to 7.5 V/cm for
15 h at 4°C. The gel was stained with 20 µl of SYBRGreenTM Nucleic Acid
Stain (Lonza Rockland, Inc., Rockland, ME) diluted in 200 ml of 1X TBE buffer
for 1 hr. Then, the gel was de-stained in 10 mM Tris, 1 mM EDTA for 30
minutes and the DNA was visualized using a Molecular Dynamics STORM
Phosphor Imager (Model 860-PC, Amersham Biosciences, Piscataway, NJ).

Southern blot analysis
Agarose gels containing electrophoresed DNA were consecutively
submerged and gently rocked twice for 15 min each in the following solutions:
1) 0.25 M HCl solution for DNA depurination, 2) 1 M NaCl, 0.5 M NaOH solution
for DNA denaturation and residual RNA removal, and 3) a neutralizing solution
containing 0.5 M Tris-HCl (pH 7.0), 1.5 M NaCl.

Treated gels were vacuum-blotted onto nitrocellulose membranes (125).
After blotting, the DNA was immobilized on the membrane by baking for 1h in a
vacuum oven at 80°C. At this point, the membrane could be either used for
hybridization or stored at -20°C. 10 ml of a prehybridization buffer is added to
the membrane at RT for 10 min. The prehybridization buffer contains 50%
formamide, 5X SSC (750 mM NaCl, 75 mM sodium citrate), 10X Denhardt’s
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solution (0.2% bovine serum albumin, 0.2% Ficoll 400 and 0.2%
polyvinylpyrrollidone), 0.05 M Na3PO4, 0.5 mg/ml salmon sperm (or total E.coli
DNA), and 0.1% SDS. 10 ml of hybridization buffer are heated at 100°C for 5
min then cooled down to RT. The hybridization buffer consists of 50%
formamide, 5X SSC, 1X Denhardt’s solution, 0.015 M Na3PO4, 0.1 mg/ml
salmon sperm, 5% dextran sulfate and 0.1% SDS. Then, prehybridization
buffer is removed; the radiolabeled probe is added to the hybridization buffer,
mixed and added to the membrane. Hybridization is performed for 16-18 h at
RT. The membrane is then washed at RT for 3-4 times with a solution
containing 0.1% SDS and 0.1X SSC. Finally, the membrane is exposed for
autoradiography for 16-24 h to a Phosphor Screen and analyzed using a
Molecular Dynamics STORM Phosphor Imager (Model 860-PC, Amersham
Biosciences, Piscataway, NJ).

Synthesis of a [γ32P]-ATP-radiolabeled probe by 5’-end labeling of DNA
oligonucleotides
Human mtDNA-derived oligonucleotides (Table 2) were mixed, at a final
concentration of 10 µg/ml, in 1X TE buffer (primer mix). Then, the radiolabeled
probe was made by adding in an eppendorf tube 1µl of primer mix to 1µl of 10X
T4 polynucleotide kinase buffer, 1 µl (10U) of T4 kinase and 7 µl of [γ32P]-dATP
isotope. The mixture was incubated for 30 min at 37°C. Then, 40 µl of a
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solution (stop buffer) consisting of 20 mM NaCl, 50 mM EDTA, 20 mM Tris-HCl
(pH 7.5), 1% SDS and 0.25% dextran blue, were added. The radiolabeled
probe was kept at RT for hybridization.

Isolation of cccDNA by alkaline cell lysis and CsCl-EtBr gradient
5x108 cells were centrifuged at 500 x g for 15 min and resuspended in
10 ml 1X PBS. Five ml of an alkaline buffer solution containing 50 mM NaCl,
2 mM EDTA, 1% SDS and 30 mM NaOH were added to the cells and the
mixture was vortexed for 2 min and incubated at 30°C for 30 min. Then, the
mixture was neutralized by addition of 80.4 μl of 1 M Tris (pH 7.0) and 200 μl of
5 M NaCl. Proteinase K (60 μg/ml) was added and mixture was incubated at
37°C for 30 min. DNA was extracted with an equal volume of 24:24:1
phenol:chloroform:isoamyl alcohol solution followed by extraction with
chloroform. DNA was then precipitated by centrifugation at 20,000 rpm at 4°C
with 2.5 volumes of 95% ethanol. DNA was air-dried and pellet was
resuspended in a 1X TE solution. Then, cesium chloride (CsCl) (1.55 g/ml final
density) and ethidium bromide (EtBr) (1μg/ml final concentration) were added.
The mixture was centrifuged at 45,000 rpm in a Beckman L7-75, VTi65 rotor for
72 h at 20°C. After 3 days, 200 µl fractions from higher density (bottom of the
tube) to lower density (top of the tube) were collected in a 96-well plate and
aliquots from each fraction were analyzed by electrophoresis in a 0.8% agarose
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gel. Fractions corresponding to cccDNA were further purified by repeated
extractions with 1 volume 5M NaCl isopropanol. The mixture containing the
cccDNA (stripped of EtBr) was mixed with 2.5 volumes of 95% ethanol,
centrifuged at 20,000 x g for 30 min at 4°C, and the pellet was resuspended in
1X TE buffer.

Cloning of fragments from EL cccDNA
Purified EL cccDNA was electrophoresed in a 0.8% low-melting
temperature agarose gel for 18 h at 22V, 4°C. The gel was stained with
SYBRGreenTM and DNA visualized in a UV-box. The band corresponding to
high MW cccDNA was cut out from the gel and incubated at 65°C for 10 min.
The cccDNA was purified by phenol/chloroform extraction and ethanol
precipitation. Cloning of EL cccDNA was performed by restriction digestion
using the four-base-cutter endonuclease Mbo I followed by T4-ligation to Bam
HI-digested and dephosphorylated pBluescript® II KS vector. Ligation mixture
was phenol/chloroform extracted, ethanol precipitated and resuspended in 10
µl of nuclease-free water.
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Electroporation of competent E. coli and selection of transformants
1 µl of ligated DNA was mixed with 10 µl of competent E. coli
(ElectroMAX DH10B strain) and incubated on ice for 10 min. The suspension
was put in a 1-mm electrode-gap cuvette and electroporated at 1,500 V using
an Eppendorf Electroporator 2510. Cells were incubated for 1h at 37°C in 500
µl of SOC medium (20 g/L bacto-tryptone, 5 g/L yeast extract, 0.5 g NaCl, 2.5
mM KCl, pH 7.0). Different dilutions of electroporated cells to SOC medium
(1:1, 1:10 and 1:100) were plated in agar plates containing ampicillin (100
µg/ml final concentration), 5-bromo-4-chloro-3-inodlyl-β-D-galactopyranoside
(X-gal) to a final concentration of 80 μg/ml (prepared in dimethylformamide,
DMF), and isopropyl-1-thio-β-D-galactopyranoside (IPTG) to a final
concentration of 20 mM (prepared in sterile ddH2O). Finally, the plates were
incubated overnight at 37°C and transformants containing EL cccDNA
fragments were selected by blue-white color screening.

PCR analysis
Purified cccDNA was electrophoresed in a low-melting temperature 0.8%
agarose gel and ran overnight at 4°C and 22 V. After 16 h, gel staining and
DNA visualization in a UV-box were performed. The gel fractions containing
cccDNA for both monomers and concatemers were cut out and melted at 65°C
for 10 min, then cccDNA was phenol/chloroform extracted and ethanol
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precipitated. Oligonucleotides were used either for amplification or as probes
for Southern blotting (Table 2) (151): PCR products were electrophoresed in a
0.8% agarose gel to confirm size (in comparison to predicted size from official
human mtDNA sequence). Then, PCR products were sequenced and analyzed
using CLC Workbench 3®.

Name

Sequence

Position (3'-end)

2F
2R
3F
3R
4F
4R
5F
5R
6F
6R
7F
7R
8F
8R
9F
9R
10F
10R
11F
11R
12F
12R
13F
13R
14F
14R

5’CGATCAACCTCACCACCTCT3’
5’TGGACAACCAGCTATCACCA3’
5’GGACTAACCCCTATACCTTCTGC3’
5’GGCAGGTCAATTTCACTGGT3’
5’AAATCTTACCCCGCCTGTTT3’
5’AGGAATGCCATTGCGATTAG3’
5’TACTTCACAAAGCGCCTTCC3’
5’ATGAAGAATAGGGCGAAGGG3’
5’TGGCTCTTTAACCTCTCCA3’
5’AAGGATTATGGATGCGGTTG3’
5’ACTAATTAATCCCCTGGCCC3’
5’CCTGGGGTGGGTTTTGTATG3’
5’CTAACCGGCTTTTTGCCC3’
5’ACCTAGAAGGTTGCCTGGCT3’
5’GAGGCCTAACCCCTGTCTTT3’
5’ATTCCGAAGCCTGGTAGGAT3’
5’CTCTTCGTCTGATCCGTCCT3’
5’AGCGAAGGCTTCTCAAATCA3’
5’ACGCCAAAATCCATTTCACT3’
5’CGGGAATTGCATCTGTTTTT3’
5’ACGAGTACACCGACTACGGC3’
5’TGGGTGGTTGGTGTAAATGA3’
5’TTTCCCCCTCTATTGATCCC3’
5’GTGGCCTTGGTATGTGCTTT3’
5’CCCACCAATCACATGCCTAT3’
5’TGTAGCCGTTGAGTTGTGGT3’

1245
2007
1854
2669
2499
3346
3169
3961
3796
4654
4485
5420
5255
6031
5855
6642
6469
7315
7148
8095
7937
8797
8621
9397
9230
10130
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15F
15R
16F
16R
17F
17R
18F
18R
19F
19R
20F
20R
21F
21R
22F
22R
23F
23R
24F
24R

5’TCTCCATCTATTGATGAGGGTCT3’
5’AATTAGGCTGTGGGTGGTTG3’
5’GCCATACTAGTCTTTGCCGC3’
5’TTGAGAATGAGTGTGAGGCG3’
5’TCACTCTCACTGCCCAAGAA3’
5’GGAGAATGGGGGATAGGTGT3’
5’TATCACTCTCCTACTTACAG3’
5’AGAAGGTTATAATTCCTACG3’
5’AAACAACCCAGCTCTCCCTAA3’
5’TCGATGATGTGGTCTTTGGA3’
5’ACATCTGTACCCACGCCTTC3’
5’AGAGGGGTCAGGGTTCATTC3’
5’GCATAATTAAACTTTACTTC3’
5’AGAATATTGAGGCGCCATTG3’
5’TGAAACTTCGGCTCACTCCT3’
5’AGCTTTGGGTGCTAATGGTG3’
5’TCATTGGACAAGTAGCATCC3’
5’GAGTGGTTAATAGGGTGATAG3’
5’CACCATTCTCCGTGAAATCA3’
5’AGGCTAAGCGTTTTGAGCTG3’

9989
10837
10672
11472
11314
12076
11948
12772
12571
13507
13338
14268
14000
14998
14856
15978
15811
5
16420
775

Table 2. Oligonucleotides used for PCR amplification and sequencing of
EL cccDNA and mtDNA of normal T-cells.
3’-end positions are relative to the revised Cambridge reference sequence of
the human mtDNA available at www.mitomap.org.
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DNA sequencing
We submitted all EL cccDNA-derived clones and purified PCR products
for sequencing to the Molecular Biology core facility at the H. Lee Moffitt
Cancer Center and Research Institute.

Electron microscopy
Mitochondrial DNA samples were prepared for electron microscope
imaging using a modified Kleinschmidt protocol (99, 213). DNA was mixed with
ammonium acetate and cytochrome C, placed on a piece of parafilm to allow a
protein monolayer to form. A carbon coated electron microscopy grid is put in
contact with the surface of the sample. Grids were washed with a solution of
95% ethanol/50 uM uranyl acetate. Grids were then either visualized as is or
rotary metal shadowed with tungsten in an Edwards Auto 306 vacuum
evaporator. The length of the DNA molecules was confirmed by comparison to
plasmids of known length. The grids were imaged in a Hitachi H7500 TEM
equipped with an Advanced Microscopy Techniques XR60 CCD camera. The
NIH Image J was used to trace the backbone of the DNA molecules and the
DNA length was calculated (EM was performed by Troy Lund and Stephen
Jett).
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Flow cytometry analysis for characterization of EL cells
1x106 EL cells and normal T-cells for controls, were resuspended in 5ml
of staining solution containing 1X PBS, 0.1% (w/v) NaN3 and 1.0% (w/v)
bovine serum albumin (BSA; fraction V) on ice. Then, cells were fluorescently
labeled using staining media containing 10 µl of each of the FITC-conjugated
antibodies used and isotype (IgG1 and IgG2) for controls, diluted to the
appropriate concentrations. Cell suspensions were analyzed in a BD
FACSCaliburTM Flow cytometer. Monoclonal mouse or goat anti-human
antibodies for the following markers were used: CD2, CD15, CD45, CD8,
CD10, CD19, CD20, CD22, CD33, HLA-DR, CD13, CD14.

Flow cytometry analysis of mitochondrial factors and properties

1. Mitochondrial membrane potential (Δψm)
Δψm was estimated by staining for 15 min at 37°C with cationic lipophilic
dye 20 nm 3,3'-dihexyloxacarbocyanine iodide (DiOC6; Molecular Probes,
Eugene, OR; excitation: 488 nm, emission: 525 nm). Fluorescence of DiOC6 is
oxidation-independent and correlates with Δψm (182). Δψm was also
quantitated by using a potential-dependent J-aggregate-forming lipophilic
cation, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine iodide
(JC-1) (173). JC-1 selectively incorporates into mitochondria, where it forms
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monomers (fluorescence in green, 527 nm) or aggregates, at high
transmembrane potentials (fluorescence in red, 590 nm) (40, 118, 173). Cells
were incubated with 0.5 μM JC-1 for 15 min at 37°C before flow cytometry.
Δψm changes were also confirmed by staining with 1 μM CMXRos (excitation:
579 nm, emission: 599 nm) and 1 μM tetramethyl rhodamine methylester
perchlorate (TMRM) (excitation: 543 nm, emission: 567 nm; Molecular Probes).
Cotreatment with a protonophore, 5 μM carbonyl cyanide mchlorophenylhydrazone (mClCCP; Sigma) for 15 min at 37°C resulted in
decreased DiOC6, CMXRos, TMRM, and JC-1 fluorescence and served as a
positive control for disruption of Δψm (9).

2. Mitochondrial mass
Mitochondrial mass was monitored by staining with potential-insensitive
mitochondrial dyes 50 nM nonyl acridine orange (NAO, excitation: 490 nm,
emission: 540 nm) or 100 nM MitoTracker green-FM (excitation: 490 nm,
emission: 516 nm; Molecular Probes). Samples were analyzed on a Becton
Dickinson Vantage S/E flow cytometer equipped with an Enterprise II argon
laser producing two laser lines (emission of 351-364 nm at 60 mW and
emission of 488 nm at 350 mW) and a Coherent (Santa Clara, CA) 70C
Spectrum krypton-argon laser operated at 200 mW (emission at 647 nm).
Dead cells and debris were excluded from the analysis by electronic gating of
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forward scatter (FSC) and side scatter (SSC) measurements. Each
measurement was carried out on 10,000 cells.

3. Production of ROS
Intracellular amounts of ROS were assessed fluorometrically using
oxidation-sensitive fluorescent probes 5,6-carboxy-2',7'-dichlorofluoresceindiacetate (DCFH-DA), dihydrorhodamine 123 (DHR), and dihydroethidium
(hydroethidine, DHE; Molecular Probes, Eugene, OR) as described (8, 9).
Cells were incubated with 0.1 μM DHR for 2 min, 1 μM DCFH-DA for 15 min, or
1 μM DHE for 15 min. Fluorescence emission from 5,6-carboxy-2',7'dichlorofluorescein (DCF; green) or DHR (green) was detected at a wavelength
of 530 ± 30 nm. Fluorescence emission from oxidized hydroethidine ethidium
(red), was detected at a wavelength of 605 nm. While R123, the fluorescent
product of DHR oxidation, binds selectively to the inner mitochondrial
membrane, the oxidized products of DCFH-DA and DHE, ethidium and
dichlorofluorescein (DCF), respectively, remain in the cytosol of living cells.
DCF and DHE preferentially detect H2O2 and superoxide (O2-), respectively (19,
90, 153).
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4. Glutathione levels
Intracellular glutathione levels were assessed with 100 μM
monochlorobimane (excitation: 380 nm/emission: 461 nm) following similar
protocols for cell staining and sample measurements as in ROS assays.

5. Fas-induced apoptosis
Apoptosis was induced with Fas Ab CH-11 (MBL, Watertown, MA).
Briefly, twenty-four hours before assays, cells were fed fresh medium and
seeded at a density of 2 x 105 cells/ml, and cell death was induced with 50 or
100 ng/ml anti-Fas mAb CH-11. Apoptosis was monitored by observing cell
shrinkage and nuclear fragmentation and was quantified by trypan blue
exclusion (191). DNA fragmentation during apoptosis was monitored by
agarose gel electrophoresis (8). Apoptosis was also measured by flow
cytometry after concurrent staining with fluorescein-conjugated annexin V
(annexin V-FITC; R&D Systems, Minneapolis, MN) and propidium iodide (122,
193). Staining with phycoerythrin-conjugated annexin V (annexin V-PE; R&D
Systems) was used to monitor phosphatidyl serine (PS) externalization in
parallel with measurement of ROS levels and Δψm, using DHR, DCF, or DiOC6
fluorescence, respectively. Staining with annexin V alone or in combination
with DHR or DiOC6 was conducted in 10mM HEPES (pH 7.4), 140 mM NaCl,
and 2.5 mM CaCl2.
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Immortalization of normal human T-cells using Herpesvirus saimiri
A monolayer of owl monkey kidney (OMK) cells grown in a 100 mm-dish
were infected with 1x105 pfu/ml of Herpesvirus saimiri (HVS) strain 484-77 for
virus propagation (127). After 1h post-infection, supernatant was removed.
Human peripheral blood leukocytes (PBL) were isolated from blood samples by
density gradient sedimentation using LymphoprepTM (ProGen) according to
manufacturer’s instructions. Then, PBL were cultured in RPMI 1640 cell media
containing 10% fetal calf serum (FCS), 4 mM L-glutamine, 50 μg/ml gentamycin
and 0.5 ug/ml of phytohemagglutinin (PHA) for 3 days. OMK cells showing
cytopathic effect were overlaid with human T-cells. Cells were maintained in
complete media with or without 20U/ml of IL-2 for around two more months
(181). Although control uninfected cultures usually died around 3-5 weeks
post-PHA stimulation, some infected PBL cultures were successfully expanded
(e.g. T-484 and 3HB6). After removal of IL-2, these cultures continuously grew
and were selected for analysis.
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Results

Method for detection of large cccDNA of AIDS-associated lymphomas
To visualize cccDNA from tumor samples suspensions the vertical gel
electrophoresis method of Gardella et al. was modified (54). One million cells
from each of the twelve AIDS-associated lymphoma samples were run in a
Gardella gel and the gel was stained with SYBRGreenTM (Figure 6). In some of
the samples, DNA bands migrating between the loading well and linear broken
DNA were observed; this range of these gels contains large (15-250 kb)
cccDNA. Four AIDS-associated lymphoma bands were positive for EBV by
Southern hybridization (not shown) and no longer studied. The remaining eight
samples were also negative for KSHV.

Identification of large cccDNA in an AIDS-associated lymphoma (EL) that
does not hybridize with EBV- or KSHV-derived probes
To further study the eight EBV- and KSHV-negative lymphomas,
formation of permanent cell lines was carried out. After a period of around 3
months in culture, one lymphoma sample (denominated EL) successfully
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Figure 6. The Gardella gel technique and visualization of large cccDNA in
an AIDS-associated lymphoma sample (EL).
One million live cells in 10% Ficoll buffer are loaded into a well of a vertical
agarose gel and digested by overlaying with a lysis buffer containing SDS and
pronase followed by electrophoresis at 22V for 3 h. Then, electrophoresis is
set at 70V for 18 h. Finally, the DNA is visualized by staining with
SYBRGreenTM. The three different molecular configurations of DNA are
indicated. Right panel shows SYBRGreenTM staining of Gardella gel containing
unknown episomal DNA from EL cells (arrow) migrating within the range of
large cccDNA.
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yielded a cell line while all other EBV/KSHV negative lymphoma samples
eventually died. Gardella gel analysis of EL cells and the derived cell line
consistently demonstrated the presence of a large cccDNA unrelated to EBV or
KSHV (Figures 6 and 7).

Phenotypic characterization of EL cells by flow cytometry
EL cells were positive for CD3, CD4 and CD45, meaning that they are a
CD4+ T-cell line. Other markers tested were: CD8 (specific for CTLs), CD16
(specific for NK cells, neutrophils, monocytes, and macrophages), CD19,
CD20, CD22 (for B-cells), CD33 (for myeloid cells) and HLA-DR (for APCs).
IgG1 and IgG2 were used as isotype controls (Figure 8).

The EL cccDNA consists of mitochondrial DNA
To determine the sequence of the EL cccDNA, the cells were expanded
in RPMI 1640 10% FCS without IL-2. CccDNA was isolated from EL cells by
alkaline lysis followed by centrifugation on a CsCl-EtBr density gradient.
Fractions of the gradient were collected and separated by low melting agarose
gel electrophoresis. Figure 9 shows that the higher CsCl density fractions
corresponding to cccDNA contained two discrete bands and the lower density
fraction contained smeared linear nuclear DNA as expected.
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Figure 7. Southern blotting analysis of EL cccDNA using probes specific
for both EBV and KSHV.
Total DNA from Gardella gels was transferred onto nitrocellulose membranes
for Southern blotting. Radiolabeled probes specific for (A) EBV or (B) KSHV
DNA do not hybridize with the large cccDNA identified in EL cells.
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Figure 8. EL cells are CD4+ T-lymphocytes.
Phenotypic characterization of EL cells using flow cytometry analysis shows
that EL cells are CD4+ T-lymphocytes. Other markers tested: IgG2, CD8,
CD16, CD19, CD20, CD22, CD33, HLA-DR.

45

Figure 9. Gel electrophoresis analysis of CsCl-EtBr gradient fractions of
total EL DNA.
Episomal cccDNA was purified from EL cells by alkaline lysis and CsCl–EtBr
gradient centrifugation. Density of gradient fractions decreases from left to
right. Fractions were analyzed by agarose gel electrophoresis followed by
SYBRGreenTM staining. Figure is representative of 7 independent experiments.
*High molecular weight genomic DNA; **genomic broken linear DNA front.
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DNA was extracted from the molten gel slice corresponding to the two
cccDNA bands and digested with restriction endonuclease MboI. The
restriction fragments were shotgun-cloned into the pBluescript™ vector
(Stratagene) and the clones were sequenced and analyzed using BLAST
(Figure 10). Results indicated that the clones contained 95% (>300 clones)
human mtDNA and ~5% (~20 clones) human chromosomal DNA randomly
derived from most human chromosomes, presumably caused by contamination
from nuclear DNA during collection of fractions (Table 3). Then, normal T-cells
were obtained from healthy blood donors and cccDNA was isolated and
compared with EL DNA. Gel electrophoresis shows that only one band was
detected in normal T-cells while EL cccDNA contained two bands (Figure 11A).
Southern hybridization of this gel using a human-mtDNA probe shows comigrating bands (slightly above the 23 kb marker) in both normal T-cell and EL
DNA. A slower-migrating cccDNA from EL cells also hybridized with the
mitochondrial probe (Figure 11B). These results support our previous data that
both forms of EL cccDNA were comprised of mtDNA. Moreover, the data show
that EL cells contain some monomeric mtDNA and a larger and more abundant
DNA hybridizing with the mtDNA probe.
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Figure 10. Schematic representation of the method performed for
isolation and analysis of EL cccDNA.
5 x 108 live cells in 10% Ficoll buffer are digested in an alkaline buffer. A
solution containing proteinase K is added to the lysate. Total DNA is purified
using phenol/chloroform extraction and ethanol precipitation. Purified DNA is
then mixed with a solution containing CsCl and EtBr, and ultracentrifuged at
40,000 x g for 72 h. At the end of the centrifugation, the bottom of the tube is
perforated with a sterile needle and fractions (from high to low density) are
collected in a 96-well plate. An aliquot from each fraction is then loaded and
run in an agarose gel. The gel is stained using SYBRGreenTM and the fractions
containing cccDNA are identified and further purified for cloning.
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Chromosome

Size of
chromosome
(Mbp)

Number of sequences
obtained from
EL cccDNA cloning

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
mtDNA

245
242
200
191
180
171
158
148
138
135
134
132
114
106
100
80
80
76
64
62
46
49
154
58
0.016

2
8
2
2
6
2
none
2
3
none
none
none
1
2
none
none
1
none
1
none
none
none
2
none
>300

Table 3. DNA sequencing results of EL cccDNA cloning.
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A)

B)

Figure 11. Gel electrophoresis and Southern blotting of purified cccDNA
from EL and normal T-cells using mtDNA-derived probes.
A) SYBRGreenTM staining of purified total cccDNA fractions from EL and
normal T-cells.
B) Southern blotting of DNA (from A) using a probe of radiolabeled human
mtDNA-specific oligonucleotides.
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The EL cccDNA is formed by tandem duplicated mitochondrial genomes.
Electron microscopy analysis of 50 molecules from purified EL circular
episomal DNA showed superhelical DNA with an average backbone contour
length of 10.3 μm (Figure 12). Compared to the human mitochondrial genome
(contour length of 5 μm) the cccDNA of EL cells consisted mainly of molecules
equivalent to duplicated mtDNA.

To confirm that the EL episomal DNA is formed by duplicated tandem
repeats, inverted repeats or rearranged mitochondrial genomes, full and partial
digestion using BamHI (a mtDNA-single-cutter restriction enzyme) was
performed. Figure 13 shows that complete digestion of EL cccDNA with BamHI
yields one 16.5 kb band. Partial digestion yielded two linear bands of
approximately 16.5 and 33 kb corresponding to putative monomers and dimers
of mtDNA. These results confirm our electron microscopy and sequencing data
that the EL episomal DNA is conformed mainly by duplicated mitochondrial
genomes organized in head-to-tail tandem orientation. Several additional
restriction enzyme digestion data also support this conclusion (not shown).
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Figure 12. Electron microscopy of EL cccDNA.
The contour length of the concatemeric mtDNA (EL cccDNA) was measured
using the Image Processing and Analysis in Java (ImageJ) software from the
NIH. DNA contour length was calculated to be around 10.3 µm. Similar results
were obtained measuring the contour length of 50 other molecules. Note: EM
was performed by Troy Lund and Stephen Jett.
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Figure 13. Complete and partial BamHI-restriction digestion of EL
cccDNA.
Banding pattern of fully digested EL cccDNA with BamHI (10U) (mtDNA single
cutter) at 30, 60 and 90 min resembles that of linear human mtDNA monomer
(16.5 kbp). Right panel shows partial digestion of EL cccDNA with BamHI
(0.1U) stopped at increasing time points (5 s, 10 s, 20 s, 40 s, 1 min, 2min,
5min, 10 min, 20 min, 40 min, 1 h). After 5 min, two bands of linear DNA are
observed representing putative human mtDNA monomers and dimers (16.5
and 33 kbp respectively).
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Cytosine insertions are present in the control region of the EL mtDNA
To determine whether the EL mtDNA has suffered minor mutations, PCR
amplification of purified EL cccDNA followed by DNA sequencing were
performed using specific mtDNA derived oligonucleotides covering the entire
mitochondrial genome (Table 2). PCR products of EL and normal T-cell DNA
were indistinguishable by agarose electrophoresis (not shown) indicating
absence of large insertions or deletions.

The D-loop, which is the main regulatory region of mtDNA replication
and transcription, has a highly-conserved C-stretch sequence (nt 311 to 315)
known as the conserved sequence box II (CSBII) that has been reported as a
mutational hotspot in primary tumors (158). Figure 14 shows that sequencing
of PCR-amplified EL mtDNA revealed two additional cytosine residues in the
monomer and in the dimer within the CSBII near the primer of mtDNA
replication. Normal T-cells did not contain additional cytosines in the CSBII
region as shown in the human mtDNA reference sequence.

54

Figure 14. Multiple sequence alignment analysis of conserved sequence
box II (CSBII) regions from EL and normal mtDNA.
Multiple DNA sequence alignments of EL cccDNA (mtDNA concatemers and
monomers) and normal mtDNA were performed using ClustalX. Shown, the
regions from the D-loop conserved sequence box II (CSBII, ranging nts 297321) from EL (C): EL mtDNA concatemer, EL (M): EL mtDNA monomer, normal
T-cell (M): normal T-cell mtDNA, and the human mtDNA reference sequence
from NCBI.
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Functional and structural mitochondrial properties of EL cells
Figure 15 summarizes various properties of EL cell mitochondria. In
comparison with Jurkat cells (selected due to reproducibility throughout
experiments and phenotypic similarity to normal T-cells (8)). EL lymphoma cells
showed increased ROS and peroxide-induced apoptosis as determined by
staining with dihydroethidium (DHE) and AnnexinV-Alexa 647, respectively.
These results suggest an unstable OXPHOS system in EL cells, since ROS
could leak through uncoupled mitochondrial complexes (I-V), thus augmenting
intrinsic pro-apoptotic signals. In contrast, monitoring of TMRM, NAO and
AnnexinV-Alexa-647 fluorescence indicated that mitochondrial membrane
potential, mitochondrial mass and Fas-mediated apoptosis were respectively
reduced in EL cells. Also, glutathione levels were significantly reduced in EL
cells, which could explain the overproduction of ROS in these cells since
glutathione works as a biological ROS scavenger (64).

Mitochondrial genome concatemers are present in primary AIDSassociated lymphomas and lymphoma cell lines
Primary AIDS-associated lymphomas and lymphoma cell lines were
screened for episomal cccDNA using the Gardella technique (Figure 16).
Southern hybridization detected two bands in control T-cells; a broader and
slower migrating circular form and a faster migrating linear form. However, all
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Figure 15. Flow cytometric analysis of mitochondrial physiological and
structural properties.
Reactive oxygen intermediates (ROI), Fas-induced apoptosis, mitochondrial
mass, mitochondrial potential and glutathione (GSH) levels in EL lymphoma
cells relative to Jurkat T-cells used as controls (8). Data represent mean ± SE
of 4 independent experiments. * P-value<0.05.

57

Figure 16. Mitochondrial genome concatemers are present in primary
AIDS-associated lymphomas and lymphoma cell lines.
Primary AIDS-associated lymphoma samples, various lymphoma cell lines and
normal peripheral T-cell controls were analyzed by the method of Gardella et al.
(54). Southern blotting analysis was performed by using human mtDNAspecific radiolabeled primer probes. Samples: AIDS-associated lymphomas
(2F7, 98-001, 98-002, EL); human body cavity lymphoma tumor cell line
positive for KSHV (BCBL-1); B-cell Burkitt’s lymphoma (Raji); H. saimiriinduced rabbit lymphoma (484Th) (126); non-Hodgkin’s lymphoma positive for
EBV and HIV (EBV-HIV-NHL).
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lymphoma cell lines contained an additional band co-migrating with EL
cccDNA. Therefore, all lymphoma cells encode both monomer and concatemer
forms of mitochondrial genomes. Small amounts of broken linear mtDNA were
also present in all samples probably due to dying of some cells. The linear
mitochondrial bands co-migrated with controls indicating lack of tandem
duplication of mtDNA. In contrast, EL cells contained a unique larger and very
strong DNA band, and a faint smaller linear mitochondrial genome. The
smaller one was co-migrating with bands from all other cells confirming the
presence of small amount of monomers in EL cells. Taken together, all
lymphoma cell lines encode both mitochondrial genome monomers and
concatemers consisting of two monomers probably due to interlinking of two
unit-length mitochondrial circles.

Total cccDNA was also purified by CsCl-EtBr density gradients from
established human lymphoma cell lines such as K562 (a chronic myeloid
leukemia cell line), Raji (an EBV-positive Burkitt’s B-cell lymphoma) and Molt3
(an acute T-cell lymphoma cell line). Results show that these cell lines also
contain mtDNA concatemers, although different monomer/concatemer ratios
were observed for each sample. An additional band running lower than
monomeric mtDNA was obtained in Raji, possibly caused by the presence of
EBV. A bar diagram using relative units from densitometric analysis of the gel
shows monomer and concatemer amounts in comparison to EL (Figure 17).
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Figure 17. Gel electrophoresis and densitometric analysis of cccDNA
from human lymphoma cell lines.
Total cccDNA was isolated from EL and established cell lines by alkaline cell
lysis and CsCl-EtBr density gradients. 5 µl of purified cccDNA from each
sample was electrophoresed in an 0.8% agarose gel for 16 h and stained using
SYBRGreenTM , then visualized in a UV-light box. CccDNA bands (monomers
or concatemers) were quantified by densitometric analysis using Image J and
plotted on a bar diagram according to relative densitometric units.
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Mitochondrial genome concatemers are associated with oncogenic
transformation of lymphoid cells
Gardella gel and Southern blotting analyses show that H. saimiriimmortalized human T-cells (T-484 and 3HB6) contain DNA bands hybridizing
with the mtDNA-derived radiolabeled probe. Some bands migrated slower than
the wild-type mitochondrial genome, representing mtDNA concatemers. A
much fainter band was also detected for normal T-cells (Figure 18).
Densitometric unit mean values between monomers versus concatemers
present per cell sample were statistically significant (P-values of 0.009 for Tcells, 0.03 for T-484 and 0.06 for 3HB6). Also, mean values between
concatemers present in T-cells versus immortalized cell lines were significant
(P-values <0.05) (Figure 19).

Statistical analysis
Student’s t-tests were performed to evaluate relative units from flow
cytometry assays of EL versus control cells to determine significance level of
variation in mitochondrial function and factors, and to compare densitometric
unit mean values of monomers and concatemers, and of concatemer relative
mean value units in normal versus H. saimiri-immortalized T-cells. A pvalue<0.05 was considered as significant.
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Figure 18. Southern blotting assay of Gardella gel of Herpesvirus saimiriimmortalized human T-cells reveals the presence of mitochondrial
genome concatemers.
Mitochondrial genome concatemers were identified in Herpesvirus saimiri–
immortalized T-cells (T-484 and 3HB6) using the Gardella technique followed
by Southern blotting using mtDNA-derived oligonucleotides. Figure is
representative of 4 independent experiments.
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Figure 19. Densitometric analysis of mitochondrial DNA from
Herpesvirus-saimiri-immortalized and normal T-cells.
Mitochondrial DNA bands (from Gardella gels) of Herpesvirus saimiriimmortalized (T-484 and 3HB6) and normal T-cells were analyzed by
densitometry. Shown, mean ± S.E., and P-values of monomer and concatemer
mean values for each sample, and of concatemer relative mean value units for
immortalized versus normal T-cells.
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Discussion

Identification of mitochondrial genome concatemers in lymphomas
In this study, a method was developed for the visualization of cccDNA in
mammalian cells based on a cell lysis method previously described (54). This
technique requires only 1x106 cells and is ideal for screening large number of
cell samples. It is rapid, reliable and can be concurrently harnessed for the
detection of existing or novel episomes of viruses and for the identification of
size alterations such as insertions, deletions and concatemerization of mtDNA.

Mitochondrial genome concatemers were identified in primary tumor
suspension samples obtained from AIDS-associated lymphoma patients and in
seven established mammalian lymphoma cell lines. These concatemers were
found to be conformed of two kinds. All lymphoma cells, except EL cells,
contained mitochondrial genome concatemers as interlinked monomers. In
contrast, most EL mitochondrial genomes are comprised of two unit length
molecules joined in head-to-tail configuration as demonstrated by several
independent methods such as Gardella gels, mtDNA complete and partial
digestions, and electron microscopy (Figure 20).
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Figure 20. Schematic model of mtDNA configurations identified in AIDSassociated lymphomas and lymphoma cell lines.
Normal T-cells contain mostly wild-type mtDNA (monomers of 16 kb), EL cells
contain mostly duplicated mitochondrial genomes (dimers of ~32 kb), and
concatemers (two or more interlocked mitochondrial genomes,
≥32 kb)
were
observed in AIDS-associated lymphomas and lymphoma cell lines analyzed.
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Proposed molecular mechanisms of mtDNA concatemer formation
Although the specific molecular mechanism for mtDNA concatemer
formation remains elusive, a considerable amount of evidence has been
reported on processes associated with mtDNA maintenance and stability which
might be responsible for the formation of mtDNA concatemers in transformed
lymphoid cells. Two mechanisms were proposed: homologous recombination
of mtDNA and mtDNA replication.

1) Homologous recombination of mtDNA
Homologous recombination (HR) occurs in all life forms, and is an
important mechanism for the repair of damaged DNA and maintenance of
chromosomal integrity (157, 178). In humans, several cancer-prone genetic
diseases (e.g. Fanconi anemia and Bloom’s syndrome) are associated with HR
dysfunction or deficiency (84, 178, 179). Moreover, mutations in the HRmediators BRCA1 and BRCA2 genes have been associated with familial breast
and ovarian cancer (75).

Although HR of the nuclear genome of eukaryotes has been extensively
studied, much less is known about HR in mitochondria. MtDNA HR has been
documented for a few organisms (50, 116, 117). In the yeast Saccharomyces
cerevisiae, an active process of mtDNA HR has been demonstrated (111, 113).
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It involves the participation of the mitochondrial homologous recombination
protein 1 (Mhr1) in the formation of HR intermediates of mtDNA, by pairing
ssDNA with homologous dsDNA forming heteroduplex joints (113), and the
resolution of recombination junctions by the cruciform cutting endonuclease
(Cce1) (88). Interestingly, Mhr1-dependent formation of concatemeric mtDNA
was observed when generating mitochondrial homoplasmic yeast cells (112).
However, mammalian homologues for either one of these proteins still remain
to be identified.

A homologue of the bacterial recombinase RecA, targeted to
mitochondria, has been identified in Arabidopsis thaliana and other eukaryotes
(85, 137). Also, a RecA homologue targeted to chloroplasts with HR and repair
activity was described (22). In humans, RecA homologues such as RAD51and
RAD52 have been cloned and are currently under intense investigation;
however, despite their important role in nuclear HR, none of these proteins has
been found in mitochondria (110). Hence, it has been hypothesized that other
proteins or mechanisms responsible for mtDNA HR (or a similar process) must
be present in mammalian mitochondria (4). Several reports have shown that
HR can also occur in human tissues. Kraytsberg et al. identified heterologous
(paternal and maternal) mtDNA in muscle tissue of an individual with paternal
inheritance of the mitochondrial genome (93). Kajander et al. detected mtDNA
HR intermediates in human heart muscle (78). Campbell and colleagues
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demonstrated that a human mitochondrial protein related to RecA can catalyze
HR of the mtDNA in vitro (186). Furthermore, spontaneously immortalized
murine and human fibroblasts, and primate and murine established fibroblasts
cell lines performed HR at frequencies around 100-fold higher than did normal
cells (187). Therefore, formation of mtDNA concatemers might occur through
genetic recombination of monomers of the mitochondrial genome, and
represents an appealing model to examine within the lymphoma context.

In two seminal papers describing genetic recombination in E. coli, Potter
H. et al. showed that DNA molecules of the plasmid ColE1 can be recovered
from wild-type cells as a set of monomer- and multimer-size rings (145, 146).
Moreover, they demonstrated that multimers are a product of genetic
recombination since bacterial host cells lacking a functional RecA gene could
no longer produce such DNA species (146). Finally, they proposed that
multimers are the result of the maturation of Holliday intermediates formed
between two monomer plasmid molecules (146).

The elucidation by Mootha and colleagues of a protein compendium for
mammalian mitochondria showed that around 50% of the proteins that form the
mitochondrial compartment do not have a bona fide mitochondrial targeting
sequence (MTS) (141). Therefore, other mechanism(s) for protein
translocation analogous to the TIM-TOM system must be present in these
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organelles (130). The identification of such mechanisms might explain how
mostly nuclear proteins such as p53 or STAT3 can take transient residence in
mitochondria (120, 205). Thus, recombinases that function in the nucleus
would also be able to translocate under certain circumstances (e.g. neoplastic
transformation, oxidative stress, etc.) by the same mechanisms and induce the
formation of concatemeric mtDNA through genetic recombination.

2) MtDNA replication
Two models for mammalian mtDNA replication have been proposed: the
strand-displacement and the strand-coupled models (Figures 4 and 5) (31).
The strand-displacement model was mainly determined by the analysis of
replication intermediates using EM (34). Due to the presence of two separated
origins of replication (OH for the heavy DNA strand, and OL for the light DNA
strand), during mtDNA replication, two types of mtDNA progeny have been
observed: The first one is a duplex circle with a newly synthesized leading
strand, and the other is a gapped circle with a partially formed lagging strand
(31). In both cases, the addition of nucleotides and strand ligation at the end of
the process of mtDNA replication result in the formation of closed circular
mtDNA monomer molecules. Therefore, a defective resolution of mtDNA
replication intermediates into mature monomer molecules could result in an
increase in the amount of concatemers. However, the presence of head-to-tail
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dimers and concatemers in transformed cells would be more in accordance to
replication intermediates observed in the strand-coupled model (31, 70).
Simultaneous bidirectional migration of newly formed leading and lagging
strands would result in circular dsDNA dimeric or concatemeric intermediates
that would be then processed to form circular monomers in normal cells.

It is widely accepted that cells undergoing oncogenic transformation
have marked differences in mtDNA expression and content (68, 190). A
prospect study on mtDNA copy number and risk of non-Hodgkin’s lymphoma
(NHL) showed that mtDNA amounts are increased in patients with chronic
lymphocytic leukemia (CLL), in Burkitt’s lymphoma and Epstein-Barr virustransformed lymphoblastoid cell lines (97). Although mtDNA configuration was
not determined in this study, it is possible that increasing amounts of
concatemers were also the reason for the overall mtDNA increase detected in
these NHL samples.

Defects in several mtDNA-replication factors have been associated to
human disorders (38). Mitochondrial genetic diseases can result from defects
in mtDNA in the form of deletions, point mutations, or depletion. These
mutations may be spontaneous, maternally inherited, or a result of inherited
nuclear defects in genes that maintain the mtDNA (38, 39). It is possible that
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formation of mtDNA concatemers results also from defects in one or more of
these factors in cells undergoing oncogenic transformation.

Differential expression of A and B subunits of DNApol-γ, mitochondrial
ssDNA-binding factor (MtssB) and the mtDNA helicase (Twinkle) has been
reported in leukocytes and in leukemic cell lines in comparison to other human
tissues (165) (Figures 21 and 22). Furthermore, mutations and SNPs in the
gene encoding the catalytic subunit of the mtDNA polymerase, DNApol-γ, have
been associated with such diverse disorders as progressive external
ophthalmoplegia (PEO), parkinsonism, Alpers syndrome, mitochondrial
neurogastrointestinal encephalomyopathy (MNGIE), and sensory ataxic
neuropathy, dysarthria, and ophthalmoparesis (SANDO) (38, 71, 115).
However, to date, the effect that mutations or SNPs in DNApol-γ (or another
factor associated with mtDNA replication) may have during neoplastic
transformation has not been addressed.
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Figure 21. DNApol-γ (subunit A and B) mRNA levels in several human
tissues and human cell lines (GNF Human Gene Atlas).
Transcript levels of subunits A and B of DNA polymerase gamma (DNApol-γ)
were determined for several human tissues and cell lines (ref. GNF Human
Gene Atlas). Highlighted with brackets, mRNA levels of normal leukocytes and
leukemic cell lines. To note, DNApol-γ mRNA levels are higher in leukocytes
(normal and cell lines) than in any other human tissue analyzed.
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Figure 22. MtssB and Twinkle mRNA levels in several human tissues and
human cell lines (from GNF Human Gene Atlas).
Transcript levels of mitochondrial single-stranded DNA binding protein (MtssB)
and mtDNA helicase (Twinkle) were determined for several human tissues and
cell lines (GNF Human Gene Atlas). Highlighted with brackets, mRNA levels of
normal leukocytes and leukemic cell lines. To note, MtssB and Twinkle mRNA
levels are higher in normal leukocytes than in any other human tissue analyzed
(including leukemic cell lines).
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Cytosine insertions in the mtDNA control region
Within the mitochondrial genome, a single major non-coding region
known as the D-loop, contains the main regulatory sequences for transcription
and replication initiation (183). DNApol-γ initiates replication at the origin bound
with the replication primer, and proceeds along one DNA strand displacing the
other strand (26, 34). In EL mitochondrial DNA, one to two cytosine insertions
were present at a highly conserved sequence block (CSB) within the D-loop,
known as CSBII. The presence of the mtDNA replication primer next to the
CSBII suggests that CSBII might be important during initiation/termination of
mtDNA replication, serving as a possible docking site for DNApol-γ (46).
Nevertheless, the lack of an effective method to study mtDNA mutations or
insertions in vivo has hindered further investigation on this phenomenon, which
may be attributed to random genetic drift or rapid clonal expansion occurring in
cells undergoing oncogenic transformation. Interestingly, insertion of C
residues in the CSBII has been described as a frequent event in mtDNA
alterations in human tumors (158). It could be possible that a higher G-C
content might affect dissociation of the RNA primer from the DNA, affecting
termination of DNA replication. Also, addition of cytosine residues might
increase the base-pairing binding strength of both DNA strands influencing
mtDNA termination and/or release of nascent molecules from parental mtDNA.
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Nucleoside analogues used in the treatment of AIDS affect mtDNA
stability
Highly active antiretroviral therapy (HAART), which includes nucleoside
analogue reverse transcriptase inhibitors (NRTIs) in combination with other
agents, has changed AIDS from a lethal illness to a chronic, manageable
disease (106). Within the list of NRTIs, azidothymidine (AZT), a thymidine
analogue that inhibits HIV reverse-transcription, has been one of the most
widely used antiretroviral drugs in the treatment of AIDS. Due to substrate
competitive inhibition, AZT can also function as a DNApol-γ inhibitor (121, 144,
212) (Figure 23). AZT treatment could result in the induction of impaired
mtDNA replication that could promote the formation of mitochondrial genome
concatemers and/or other mtDNA abnormalities, which may be associated to
oncogenic transformation in individuals with AIDS. It is also recognized that
mitochondrial functions are affected as a result of NRTI therapy (109). Cardiac
dysfunction, hepatic failure, skeletal myopathy, lactic acidosis with defective
mtDNA replication, mtDNA depletion and altered mitochondrial ultrastructure
have been observed in selected tissues in vivo and in post-HAART patients
(105, 107).
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Figure 23. Inhibition of DNA polymerase gamma by NRTIs (AZT).
Diagram shows the structure of the mitochondrion. The nucleoside reverse
transcriptase inhibitor, AZT, is phosphorylated by thymidine kinase 2 (TK2), the
mitochondrial isoform, thus initiating a series of steps that lead to the formation
of the active form. DNApol-γ, is inhibited by NRTI triphosphates (e.g. AZT-TP)
to deplete mtDNA by competitive inhibition with the normal pool of nucleotide
triphosphates. Adapted from reference 106.

76

Mitochondrial genome concatemers influence cellular and mitochondrial
functions
The mtDNA encodes only 1% of the mitochondrial proteins; however, it
is crucial for mitochondrial stability. The mtDNA-encoded genes are essential
subunits for OXPHOS system assembly and function. Therefore, the mtDNA is
necessary for cellular energy production in the form of ATP through OXPHOS
from dietary metabolites (172).

Variations in the mtDNA are highly detrimental for cellular homeostasis
(38, 115). Full and partial deletions of the mtDNA have been reported in
several conditions including mitochondrial myopathies (69), Kearns-Sayre
syndrome (104), PEO (214) and Pearson syndrome (154). More than 200 point
mutations and rearrangements of the mtDNA have also been associated with
human disease (29, 103), and some of them have been directly linked to
tumorigenesis (18, 27). Penta JS et al. proposed that it is possible that the
oxidatively stressed environment of tumors may result in high rates of mtDNA
mutations and reduced expression of mtDNA-encoded polypeptides (142).
Strikingly, mutated mtDNA in tumors has been found as mostly homoplasmic,
meaning that all cells within a tumor carry the same mtDNA mutation, a
phenomenon that suggests selective advantage to these mutations (138).
Recently, it was reported that particular mtDNA mutations can contribute to
tumor progression. Cells bearing a mutation in the mtDNA gene encoding
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NADH dehydrogenase subunit 6 (ND6), have a defective respiratory complex I
and subsequently overproduce ROS that increase metastatic potential (73).
Nevertheless, dimerization or concatemerization of the mtDNA have not been
related to any cellular disorder so far. This dissertation shows evidence that
formation of mtDNA concatemers is associated with changes in mitochondrial
function and with neoplastic transformation in lymphoid cells.

In this study, several significant alterations in mitochondrial functions and
cellular factors associated with mitochondria in EL cells were identified.
Probably the decrease in Fas-mediated apoptosis is most noteworthy. It has
been shown that tumor cells often escape immune surveillance by downregulating the Fas pathway or by using it to their advantage (91). For example,
some tumors increase Fas ligand (FasL) expression to induce apoptosis of
infiltrating lymphocytes (92). Also, some viruses can promote their propagation
by expressing Fas-inhibitory proteins (11, 185). In regards to mtDNA, the
cleavage and cytoplasmic release of cytochrome b (a mtDNA-encoded protein)
has been directly linked to Fas-induced apoptosis (91). However, more studies
are required to evaluate whether these changes in EL cells are a consequence
of malignant transformation or represent the result of mtDNA duplication and
mutation.
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Increased intracellular ROS
The role that intracellular ROS play in cellular biology has been
controversial. ROS are highly reactive due to the presence of unpaired valence
shell electrons. Therefore, during environmental stress, ROS levels increase
(presumably within the mM range) and cause random deleterious oxidation of
macromolecules, a condition known as oxidative stress (102, 114). MtDNA is
constantly subjected to oxidative damage due to direct exposure to ROS as
direct byproducts of OXPHOS. This damage results in mutations in the
mtDNA, which are associated with aging and various mitochondrial disorders
(79). On the other hand, the treatment of human cells with hydrogen peroxide
results in a transient increase in mtDNA copy number, suggesting that ROS
can regulate mtDNA replication (207). Furthermore, the amount of mtDNA
correlates with ROS levels in cell lines carrying different mouse mtDNA
haplotypes (132).

Contrary to their role as inducers of cellular toxicity, several lines of
evidence have shown that high ROS levels are associated with cell survival by
deregulation of the PI3-kinase/Akt pathway during tumorigenesis (35, 52).
Moreover, mitochondrial ROS could also contribute to neoplastic
transformation, both as a tumor inducer by causing mutations in the nuclear
DNA in proto-oncogenes and tumor-suppressor genes, and as a tumor
promoter through promoting cellular proliferation (198). At low levels (within the
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µM range), ROS have been found to be active mitogens. ROS are presumed
to act through interaction with various kinases including Src kinase, protein
kinase C, MAPK, and receptor tyrosine kinases, and with several transcription
factors such as Fos, Jun and NF-κB (124). A significant reduction of
glutathione levels was observed in EL cells. This may be associated with the
elevation in ROS production, since glutathione works as a biological scavenger
of ROS (64).

Herpesvirus saimiri-immortalized human T-cells contain mitochondrial
genome concatemers
In order to determine if cells undergoing transformation were able to
produce concatemers of mtDNA similar to the ones observed in the primary
AIDS-associated lymphomas and lymphoma cell lines studied, immortalization
of normal T-cells by infection with Herpesvirus saimiri was performed. This
experimental approach was chosen because it has been successfully used in
the past to obtain human, rabbit and marmoset transformed T-cell lines (126,
127, 181).

Discrete bands of mtDNA concatemers were detected by Southern
blotting in the T-cell lines T-484 and BH36, immortalized with H.saimiri.
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Additionally, a fainter band representing a small amount of concatemers was
also detected in normal T-cells. This indicates that the process of formation of
concatemers might also take place under normal conditions; however,
resolution of concatemers into monomers might be defective in neoplastically
transformed cells resulting in accumulation of concatemers.

Statistical analysis of relative densitometric units shows that the mean
values between concatemer and monomer amounts for each sample is
significant (P-values<0.005). This means that there may be an intrinsic
mechanism that keeps total mtDNA amounts (and possibly
concatemer/monomer ratios) relatively constant within these cells. Notably, the
higher amount of concatemers in immortalized T-cells was also statistically
significant (P-value<0.002) in comparison to the much lower levels detected in
normal T-cells. This implies that formation and maintenance of mtDNA
concatemers is a condition associated with immortalization of T-cells.
However, further experiments would be necessary to determine whether
mtDNA concatemers can promote oncogenic transformation of normal cells, or
if they result as byproducts of cellular growth and proliferation observed in
cancer.
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Proposed mechanism of neoplastic transformation of lymphoid cells by
formation and maintenance of mtDNA concatemers
Cellular homeostasis and energy production rely heavily on mtDNA
stability (177). Mutations in the mtDNA have long been linked to the
development and poor prognosis of various types of cancers (14, 27, 55, 73,
138). The physiological significance of mtDNA mutations in cancer cells was
demonstrated by introducing a known pathogenic mtDNA mutation into the
prostate cancer cell line PC3 via transmitochondrial cybrid fusions (143).
Injection of these mutant and wild-type PC3 cybrids into nude mice gave a
dramatic result. The PC3 cells containing the normal base (T8993T) barely
grew at all. By contrast, the PC3 cybrids with the mutant base (T8993G)
generated rapidly growing tumors that killed the mice (143). Staining the
cellular nodules from both conditions revealed that the mutant tumors produced
much more ROS than the wild-type nodules. Thus, underscoring the
generation of increased ROS, associated with mutant mtDNA, in the
pathophysiology of cancer (143).

Neoplastically transformed cells, however, can also harbor non-mutated
mtDNA (198). Therefore, the presence of mitochondrial genome concatemers
may represent an alternative mechanism of increasing intracellular ROS levels,
as detected in EL cells. Recently, Lan Q. et al showed that increased mtDNA
copy number was associated with a higher risk of developing non-Hodking’s
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lymphoma (NHL) by analyzing blood samples from 208 NHL and healthy
individuals (97). This dissertation shows evidence that, independent of
configuration, overall mtDNA levels are increased in AIDS-associated
lymphomas, in lymphoma cell lines and in immortalized T-cells. Formation of
mtDNA concatemers is also associated with higher mtDNA levels observed in
these samples. Furthermore, imbalance and lower coupling efficiency of the
OXPHOS system have been reported in cells with abnormal mtDNA content
(67, 211). Defects in OXPHOS have long been known as causative of
increased ROS levels (49, 56, 87, 102). The diffusion of ROS into the nucleus
can then mutate proto-oncogenes, converting them into functional oncogenes.
Increased cytosolic and nuclear ROS activate a variety of cellular signal
transduction factors including NFκB, APE-1, Fos, Jun, and tyrosine kinases,
which drive the cell into replication. Consequently, variations in the mtDNA
(content and/or mutations) capable of affecting the normal function of the
OXPHOS machinery, result in chronically increased mitochondrial ROS
production, which can act as both a tumor initiator (mutation of protooncogenes) and tumor promoter (activation of transcription and replication) (87,
176, 197) (Figure 24).
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Figure 24. Schematic diagram of proposed mechanism of induction of
oncogenic transformation by formation and maintenance of mitochondrial
genome concatemers.
Cells containing mitochondrial genome concatemers show increased mtDNA
levels (Figure 19) and higher ROS production (Figure 15). Neoplastically
transformed cells upregulate mtDNA gene expression (190) generally resulting
in a defective (uncoupled) OXPHOS system (14, 73), which can also produce
higher ROS levels. ROS can inhibit tumor suppressor factors (p16ink4a, p53)
and induce transcription factor activation (AP-1, NF-B, APE), which results in
cellular proliferation (176, 198).
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Finally, these experiments have established a clear correlation between
mtDNA concatemerization and malignancy of lymphoid cells. However, it is not
clear whether concatemerization is a contributing factor to oncogenesis, or
alternatively, a result of continuing growth of immortalized cells. Resolution of
these possible alternatives requires further investigation.

Summary and future directions
The development of techniques to study cccDNAs has been of
importance in the understanding of the etiology of human diseases. This
dissertation describes an experimental approach developed in our laboratory,
and by which a novel extrachromosomal cccDNA was identified in AIDS-related
lymphomas and lymphoma cell lines. This cccDNA is conformed by
concatemers of the mitochondrial genome. Moreover, by immortalizing normal
human lymphocytes with Herpesvirus saimiri, it was demonstrated that
formation of mitochondrial genome concatemers is associated with oncogenic
transformation of lymphoid cells.

In order to determine the relationship between formation of mtDNA
concatemers and oncogenic transformation, two strategies are proposed. First,
the fabrication and study of transmitochondrial cybrids using cells containing
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either wild-type or concatemeric mtDNA, with similar nuclear backgrounds, will
determine whether the presence of concatemers is sufficient to induce
neoplastic transformation. And second, the study of T-cells immortalized with
Herpesvirus saimiri could be useful to demonstrate if mtDNA concatemers are
simply byproducts of cellular immortalization. Additionally, an increasing timepoint assay after viral infection is proposed to determine when
concatemerization of the mtDNA takes place in these cells. Further studies on
the mechanism of formation and biological significance of mtDNA concatemers
may provide a new avenue in the chemotherapeutic treatment of lymphoma.
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